Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, RSV and Shingles
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody concentrations (immune response to Shingrix) and RSV-A and RSV-B neutralization titers increased from pre- to post-vaccination.
Good signs for co administration of GSK’s RSV and shingles vaccines
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial showed that co-administering Arexvy (RSV vaccine) and Shingrix (shingles vaccine) in adults 50+ produced a non-inferior immune response and was well tolerated.
GSK makes Brooke Shields the star of shingles vaccination push
GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and up about the power that comes from aging and how shingles threatens their health.
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The results will support regulatory submissions to the FDA and EMA.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK Shingles Vaccine in Malaysia: Here’s What You Need to Know
GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side effects, for whom and where to get it.
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
Joplin Globe
1d
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
Please see full Prescribing Information for
SHINGRIX
. About the NCT05966090 trial The co-administration study is a phase 3, open-label, multi-country study to assess non-inferiority of immune ...
1d
Jefferies Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Kentucky judge fatally shot
Makes MLB history
COVID, Wuhan market link
Rally attendees injured
Ban called for in TX schools
To get a second moon
To receive Holbrooke award
30 yrs in prison for assault
Gun case sentencing delay
Man charged for threats
NYC subway joyride arrest
Dow, S&P hit record highs
Hails economic progress
Statue damaged by vandal
Retires after 17 seasons
Brazil threatens daily fines
Sets new WNBA record
FTC on privacy controls
AC mayor, wife indicted
US healthcare system falls
EU warns Apple
160M euros to Ukraine
Deal to build new arena
Israel strikes Hezbollah
Los Angeles dengue cases
Existing home sales drop
Launches AI assistant
Retaliated against scientists
New SEC stock pricing rule
Cancer deaths decline
Toy Hall of Fame finalists
Related topics
RSV
GlaxoSmithKline
Rous sarcoma virus
Feedback